| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q2 2020 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NOVO-NORDISK A S | 7 | Q2 2024 | 25.8% |
| MERCK & CO INC | 7 | Q2 2024 | 14.1% |
| LILLY ELI & CO | 7 | Q2 2024 | 16.2% |
| ARGENX SE | 7 | Q2 2024 | 12.3% |
| ASTRAZENECA PLC | 7 | Q2 2024 | 5.4% |
| VIKING THERAPEUTICS INC | 7 | Q2 2024 | 7.1% |
| NEUROCRINE BIOSCIENCES INC | 7 | Q2 2024 | 2.1% |
| INTRA-CELLULAR THERAPIES INC | 7 | Q2 2024 | 2.9% |
| ABBVIE INC | 6 | Q1 2024 | 5.6% |
| VERTEX PHARMACEUTICALS INC | 6 | Q2 2024 | 2.6% |
View Artia Global Partners LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-29 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
View Artia Global Partners LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.